PIK3CA and breast carcinoma: Since in 0% GF PI 3-kinase activity appears to control the cell cycle in lines harboring the PIK3CA H1047R mutation, we studied cell cycling in the presence of 1 or 5 μM BYL719, which is the specific PI3-kinase α inhibitor approved for breast cancer treatment under the name of Alpelisib.